Page 85 - Haematologica May 2022

Analysis of older cHL patients in ECHELON-1
Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. AGal reports consultancy and speakers bureau for Takeda. W-SK has declared no conflicts of interest.
Contributions
Data were verified by the sponsor, analyzed by sponsor statis- ticians, and interpreted by academic authors and sponsor repre- sentatives. The manuscript was prepared by the authors with the assistance of a medical writer funded by the sponsor. Data were collected, and study procedures were overseen by AME, JMC, AY, SMA, WSK, JR, TF, JT, KJS, YO, AG, CP, MD-D, and AGal; data were verified by KF, AF-T, RL, HT, and AGal, analyzed by RL, and interpreted by all authors. All authors had full access to the data during development of the manuscript. All authors vouch for completeness and accuracy of the data and had final responsi- bility for the manuscript content and decision to submit.
Acknowledgments
The authors would like to thank the patients who participated in this study and their families. They would also like to acknowl- edge other investigators and staff at all ECHELON-1 clinical sites and the members of the Independent Data Monitoring Committee and Independent Review Committee. The authors
acknowledge the writing assistance of Laura Webb and Hedley Coppock of Ashfield MedComms, an Ashfield Health company, part of UDG Healthcare plc, during the development of this manuscript, which was funded by Millennium Pharmaceuticals, Inc., and complied with the Good Publication Practice 3 ethical guidelines.39
Funding
This work was supported by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (grant number not applicable); and Seagen, Inc., Bothell, WA, USA (grant number not applicable).
Data-sharing statement
The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participant’s data sup- porting the results reported in this article, will be made available within 3 months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.
References
1. Thyss A, Saada E, Gastaud L, Peyrade F, Re D. Hodgkin's lymphoma in older patients: an orphan disease? Mediterr J Hematol Infect Dis. 2014;6(1):e2014050.
2. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012;119(25):6005-6015.
3. Stark GL, Wood KM, Jack F, et al. Hodgkin's disease in the elderly: a population-based study. Br J Haematol. 2002;119(2):432-440.
4. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol. 2005;23(22):5052-5060.
5. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76-86.
6. Evens AM, Hong F. How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol. 2013;31(12):1502- 1505.
7. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elder- ly). Ann Oncol. 2005;16(1):124-131.
8. Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elder- ly Hodgkin lymphoma: outcomes and prog- nostic factors in the modern era. Blood. 2012;119(3):692-695.
9.Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016; 127(18):2189-2192.
10. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: fre- quent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179-184.
11. Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120(2):617-624.
12. Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005;23(30):7614-7620.
13. Thomas TS, Luo S, Reagan PM, et al. Advancing age and the risk of bleomycin pul- monary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin lym- phoma. J Geriatr Oncol. 2020;11(1):69-74.
14. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lym- phoma patients aged 60 years and older. Blood. 2015;126(26):2798-2804.
15. Gibb A, Pirrie SJ, Linton K, et al. Results of a UK National Cancer Research Institute phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVI- TY). Br J Haematol. 2020;193(1):63-71.
16. Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in com- bination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017;130(26):2829-2837.
17. Gallamini A, Bijou F, Viotti J, et al. Brentuximab-vedotin and bendamustine is a feasible and effective drug combination as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial). Hematol Oncol. 2017;35(Suppl 2):170.
18. Fosså A, Böll B, Goergen H, et al. T021 (0147) B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and pred- niso(lo)Ne) in older patients with advanced- stage Hodgkin lymphoma: results of a phase
II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). HemaSphere. 2018;2:27.
19. Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vin- blastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018; 36(30):3015-3022.
20. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331-344.
21. Straus DJ, Diugosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemother- apy for stage III/IV classical Hodgkin lym- phoma: 3-year update of the ECHELON-1 study. Blood. 2020;135(10):735-742.
22. Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, ran- domised, phase 3 trial. Lancet Haematol. 2021;8(6):e410-e421.
23. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lym- phoma. J Clin Oncol. 2007;25(5):579-586.
24. Friedberg JW, Forero-Torres A, Holkova B, et al. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. J Clin Oncol. 2018;36(Suppl 15):7542.
25. Yasenchak CA, Bordoni R, Patel-Donnelly D, et al. Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. Blood. 2020; 136(Suppl 1):18-19.
26. Yasenchak CA, Bordoni R, Yazbeck V, et al. Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged ≥60 years. Blood. 2019;134(Suppl 1):237.
27.Cheson BD, Bartlett NL, LaPlant B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-
haematologica | 2022; 107(5)
1093